FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379523560> ?p ?o ?g. }

• W4379523560 endingPage "734" @default.
• W4379523560 startingPage "734.1" @default.
• W4379523560 abstract "Background JAK inhibitors (JAKi) are a new class of drugs developed for the treatment of different immune-mediated inflammatory diseases (IMIDs). Thrombotic events have been reported in some long-term extension studies as adverse effects. As a consequence, in 2017 the Food and Drug Administration (FDA) inserted a black box warning in the Summary of Product Characteristics (SPC) for Baricitinib, stating that it should be used with caution in patients at increased risk of thrombosis [1]. A similar warning was issued by the European Medicines Agency (EMA) in 2019 for Tofacitinib 10 mg [2]. Objectives To perform a systematic review of randomized controlled trials (RCTs) with the aim to estimate the risk of venous and arterial thromboembolic (TE) events in patients with IMIDs treated with JAKi. Methods RCTs on the efficacy and safety of JAKi in IMIDs patients were identified by electronic search of the MEDLINE and EMBASE database until October 2021. Risk of bias was assessed according to Cochrane criteria. All JAKi and all IMIDs were included in the main analysis. Venous and arterial TE events (deep vein thrombosis, pulmonary embolism, unusual site thrombosis, superficial venous thrombosis, stroke, transient ischemic attack, coronary ischaemic events and peripheral artery ischaemia) and major adverse cardiovascular events (MACE) were extracted from the reported safety analysis of the different RCTs. Studies which did not report any information on the cardiovascular safety profile in the paper or supplementary materials were excluded. Differences in thrombotic outcomes among groups were expressed as pooled odds ratio (OR) and corresponding 95% confidence interval (CI), using both a fixed-effects and a random-effects model. Statistical heterogeneity was evaluated using the I² statistic. Results One phase I, 21 phase II, 3 phase II-III and 36 phase III RCTs on Rheumatoid Arthritis (32.8%), Atopic Dermatitis (22.9%), Psoriasis (11.5%), Inflammatory Bowel Disease (11.5%), Psoriatic Arthritis (9.8%), Ankylosing Spondylitis (6.6%) and Lupus Erytheratosus (4.9%) were included, for a total of 19443 patients in the JAKi group (Abrocitinib, Baricitinib, Brepocitinib Deucravacitinib, Filgotinib, Ivarmacitinib, Peficitinib, Tofacitinib and Upadacitinib) and 9073 in the placebo group. Thirty-one (unweighted rate 0.16%) TE events were reported in the JAKi group and 20 (unweighted rate 0.22%) in the control group in an unweighted mean follow-up of 16.8 weeks. IMIDs patients treated with JAKi had not an increased TE risk compared to IMIDs patients treated with placebo (OR 0.69 [95% CI, 0.44–1.10, I 2 0%] at fixed-effect model) (Figure 1). No clinically relevant results were seen among different IMIDs and drugs. The ORs of venous and arterial TE events were respectively 0.61 (95% CI, 0.32–1.15, I 2 0%) and 0.78 (95% CI, 0.41–1.48, I 2 0%) at fixed-effect model. The incidence of MACE was similar among the groups (OR 0.82 [95% CI, 0.48–1.40, I 2 0%] at fixed-effect model). Conclusion Despite our study has some limits like the short duration of the RCTs, the different inclusion criterias, permitted concomitant therapies, mean age and mean disease activity, we did not find any evidence that JAKi increase the risk of venous and arterial TE events and MACE. The performed sub-analysis did not find any correlation between the use of any JAKi and TE events in any considered IMID, even if the meta-analysis is likely underpowered (i.e. β error) to highlight statistically significant differences of the incidence of TE events between different diseases and different JAKi. JAKi do not increase TE risk compared to placebo in IMIDs patients enrolled in phase I/II/III RCTs. References [1]Olumiant (baricitinib) prescribing information. Indianapolis (IN): Lilly; 2018. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf [2]EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. URL: https://www.ema.europa.eu/en/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf Figure 1. Acknowledgements Andrea Zaffaroni took part in this study as participant to the scientific research training project for medical students of the University of Insubria, Italy, named ‘Recruiting and training physicians-scientists to empower translational research. A multilevel transdisciplinary approach focused on methodology, ethics and integrity in biomedical research - 2018-2023’ and funded by Fondazione Cariplo, Italy. Disclosure of Interests None Declared." @default.
• W4379523560 created "2023-06-07" @default.
• W4379523560 creator A5046394483 @default.
• W4379523560 creator A5055891755 @default.
• W4379523560 creator A5060276155 @default.
• W4379523560 creator A5064718795 @default.
• W4379523560 creator A5076566785 @default.
• W4379523560 creator A5084997106 @default.
• W4379523560 date "2023-05-30" @default.
• W4379523560 modified "2023-09-27" @default.
• W4379523560 title "POS0859 VENOUS AND ARTERIAL THROMBOEMBOLIC RISK OF JAK INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS" @default.
• W4379523560 doi "https://doi.org/10.1136/annrheumdis-2023-eular.5320" @default.
• W4379523560 hasPublicationYear "2023" @default.
• W4379523560 type Work @default.
• W4379523560 citedByCount "0" @default.
• W4379523560 crossrefType "journal-article" @default.
• W4379523560 hasAuthorship W4379523560A5046394483 @default.
• W4379523560 hasAuthorship W4379523560A5055891755 @default.
• W4379523560 hasAuthorship W4379523560A5060276155 @default.
• W4379523560 hasAuthorship W4379523560A5064718795 @default.
• W4379523560 hasAuthorship W4379523560A5076566785 @default.
• W4379523560 hasAuthorship W4379523560A5084997106 @default.
• W4379523560 hasBestOaLocation W43795235601 @default.
• W4379523560 hasConcept C126322002 @default.
• W4379523560 hasConcept C141071460 @default.
• W4379523560 hasConcept C156957248 @default.
• W4379523560 hasConcept C164705383 @default.
• W4379523560 hasConcept C168563851 @default.
• W4379523560 hasConcept C197934379 @default.
• W4379523560 hasConcept C2776265017 @default.
• W4379523560 hasConcept C2777575956 @default.
• W4379523560 hasConcept C2778886723 @default.
• W4379523560 hasConcept C2778959117 @default.
• W4379523560 hasConcept C2780011451 @default.
• W4379523560 hasConcept C2780868729 @default.
• W4379523560 hasConcept C71924100 @default.
• W4379523560 hasConcept C95190672 @default.
• W4379523560 hasConceptScore W4379523560C126322002 @default.
• W4379523560 hasConceptScore W4379523560C141071460 @default.
• W4379523560 hasConceptScore W4379523560C156957248 @default.
• W4379523560 hasConceptScore W4379523560C164705383 @default.
• W4379523560 hasConceptScore W4379523560C168563851 @default.
• W4379523560 hasConceptScore W4379523560C197934379 @default.
• W4379523560 hasConceptScore W4379523560C2776265017 @default.
• W4379523560 hasConceptScore W4379523560C2777575956 @default.
• W4379523560 hasConceptScore W4379523560C2778886723 @default.
• W4379523560 hasConceptScore W4379523560C2778959117 @default.
• W4379523560 hasConceptScore W4379523560C2780011451 @default.
• W4379523560 hasConceptScore W4379523560C2780868729 @default.
• W4379523560 hasConceptScore W4379523560C71924100 @default.
• W4379523560 hasConceptScore W4379523560C95190672 @default.
• W4379523560 hasIssue "Suppl 1" @default.
• W4379523560 hasLocation W43795235601 @default.
• W4379523560 hasOpenAccess W4379523560 @default.
• W4379523560 hasPrimaryLocation W43795235601 @default.
• W4379523560 hasRelatedWork W1988855938 @default.
• W4379523560 hasRelatedWork W2171652010 @default.
• W4379523560 hasRelatedWork W2410487325 @default.
• W4379523560 hasRelatedWork W2463152737 @default.
• W4379523560 hasRelatedWork W2463643367 @default.
• W4379523560 hasRelatedWork W2981730791 @default.
• W4379523560 hasRelatedWork W2999314198 @default.
• W4379523560 hasRelatedWork W3022042949 @default.
• W4379523560 hasRelatedWork W4290193190 @default.
• W4379523560 hasRelatedWork W1603374058 @default.
• W4379523560 hasVolume "82" @default.
• W4379523560 isParatext "false" @default.
• W4379523560 isRetracted "false" @default.
• W4379523560 workType "article" @default.